A. Mathioudakis (Manchester, United Kingdom), M. Cazzola (Roma (RM), Italy), H. Kerstjens (Groningen, Netherlands), I. Bonovolias (Thessaloniki, Greece)
Dual bronchodilator response according to bronchitis symptoms in the FLAME study
A. Mackay (London, United Kingdom), K. Kostikas (Basel, United Kingdom), S. Frent (Timisoara, Romania), K. Mezzi (Basel, United Kingdom), P. Pfister (Basel, United Kingdom), P. Gupta (Hyderabad, United Kingdom), F. Patalano (Basel, United Kingdom), D. Banerji (East Hanover, United Kingdom), J. Wedzicha (London, United Kingdom)
|   |
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis
S. Muro (Kyoto, Japan), H. Yoshisue (Tokyo, Japan), A. Mackay (London, United Kingdom), K. Kostikas (Basel, Switzerland), P. Olsson (Taby, Sweden), P. Gupta (Hyderabad, India), J. Wedzicha (London, United Kingdom)
| |
Estimating potential cost savings associated with managing COPD according to GOLD 2017 recommendations in UK primary care: a CPRD study
A. Mathioudakis (Manchester, United Kingdom), J. Vestbo (Manchester, United Kingdom), A. Gayle (Bracknell, United Kingdom), S. Dickinson (Bracknell, United Kingdom), K. Morris (Bracknell, United Kingdom), S. Webster (Bracknell, United Kingdom), C. Poole (Bracknell, United Kingdom)
| |
Indacaterol/glycopyrronium increases lung ventilation in COPD patients as measured by hyperpolarized 3He MRI
H. Tillmann (Basel, Switzerland), D. Singh (Manchester, United Kingdom), D. Saralaya (Bradford, United Kingdom), R. Lawson (Sheffield, United Kingdom), J. Wild (Sheffield, United Kingdom), J. Goldin (Los Angeles, United States of America), K. Kostikas (Basel, Switzerland), K. Smith (Cambridge, United States of America), S. Machineni (Hyderabad, India), D. Yates (Cambridge, United States of America)
| |
Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
G. Ferguson (Farmington Hills, United States of America), A. Shaikh (Ridgefield, United States of America), K. Tetzlaff (Biberach an der Riss, Germany), A. Mueller (Biberach an der Riss, Germany), H. Watz (Grosshansdorf, Germany)
| |
Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study
S. Anees (Windsor, Canada), A. Mcivor (Hamilton, Canada), K. Chapman (Toronto, Canada), I. Mayers (Edmonton, Canada), D. Rochdi (Dorval, Canada), D. Prefontaine (Dorval, Canada), A. Kaplan (Toronto, Canada)
| |
Extrafine beclometasone dipropionate, formoterol fumarate, glycopyrronium (BDP/FF/G) and exacerbation recurrence: post-hoc analysis of the TRIBUTE study.
L. Fabbri (Ferrara, Italy), D. Singh (Manchester, United Kingdom), J. Vestbo (Manchester, United Kingdom), M. Corradi (Parma, Italy), A. Guasconi (Parma, Italy), M. Scuri (Parma, Italy), G. Georges (Parma, Italy), I. Montagna (Parma, Italy), H. Prunier (Parma, Italy), S. Vezzoli (Parma, Italy), S. Petruzzelli (Parma, Italy), A. Papi (Ferrara, Italy)
| |
Pharmacological treatment of stable Chronic Obstructive Pulmonary Disease: Where do we stand?
F. Chermiti Ben Abdallah (Ariana, Tunisia), M. Kacem (Ariana, Tunisia), I. Bachouch (Ariana, Tunisia), N. Belloumi (Ariana, Tunisia), Y. Hdidene (Ariana, Tunisia), S. Fenniche (Ariana, Tunisia)
| |
FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial
D. Singh (Manchester, United Kingdom), F. Barnhart (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, United States of America), C. Jones (Research Triangle Park, United States of America), S. Kilbride (Uxbridge, United Kingdom), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Mouneimne (Brentford, United Kingdom), R. Wise (Baltimore, United States of America), D. Lipson (Philadelphia, United States of America)
| |
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
D. Lipson (Pennsylvania, United States of America), F. Barnhart (Research Triangle Park, United States of America), I. Boucot (Brentford, United Kingdom), C. Crim (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), D. Halpin (Exeter, United Kingdom), S. Kilbride (Uxbridge, United Kingdom), M. Han (Ann Arbor, United States of America), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), I. Naya (Brentford, United Kingdom), C. Jones (Research Triangle Park, United States of America), R. Wise (Baltimore, United States of America)
| |
Comparison of LAMA/LABA vs ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial
D. Lipson (Pennsylvania, United States of America), F. Barnhart (Research Triangle Park, United States of America), I. Boucot (Brentford, United Kingdom), C. Crim (Research Triangle Park, United States of America), N. Brealey (Uxbridge, United Kingdom), G. Criner (Philadelpha , United States of America), M. Dransfield (Birmingham , United States of America), D. Halpin (Exeter, United Kingdom), S. Kilbride (Uxbridge, United Kingdom), M. Han (Ann Arbor, United States of America), P. Lange (Copenhagen, Denmark), D. Lomas (London, United Kingdom), F. Martinez (New York, United States of America), D. Singh (Manchester, United Kingdom), I. Naya (Brentford, United Kingdom), C. Jones (Research Triangle Park, United States of America), R. Wise (Baltimore, United States of America)
| |
LABA/LAMA combinations efficacy evaluation therapy of COPD patients with emphasized morning and night symptoms
T. Pavlovic (Belgrade, Republic of Serbia), D. Pavlovic (Belgrade, Republic of Serbia), M. Vukcevic (Belgrade, Republic of Serbia), V. Žugic (Belgrade, Republic of Serbia)
| |
Baseline symptom burden and dual bronchodilator response in the FLAME study
A. Mackay (London, United Kingdom), K. Kostikas (Basel, Switzerland), S. Frent (Timisoara, Romania), P. Olsson (Täby, Sweden), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), F. Patalano (Basel, Switzerland), D. Banerji (East Hanover, United States of America), J. Wedzicha (London, United Kingdom)
| |
Indacaterol/Glycopyrronium improves pulmonary ventilation and ventilation inhomogeneity in the CLAIM Study
J. Vogel-Claussen (Hannover, Germany), T. Kaireit (Hannover, Germany), A. Voskrebenzev (Hannover, Germany), C. Schoenfeld (Hannover, Germany), C. Czerner (Hannover, Germany), J. Renne (Hannover, Germany), H. Tillmann (Basel, Switzerland), K. Berschneider (Nuremberg, Germany), S. Hiltl (Nuremberg, Germany), J. Bauersachs (Hannover, Germany), T. Welte (Hannover, Germany), J. Hohlfeld (Hannover, Germany)
| |
Comparison of dual vs triple therapies in patients hospitalized for COPD in France: a claims data study
F. Dalon (Lyon, France), N. Roche (Paris, France), M. Belhassen (Lyon, France), M. Nolin (Lyon, France), D. Vesque (Bois-Colombes, France), P. Devillier (Suresnes, France), G. Deslee (Reims, France), B. Housset (Créteil, France), H. Pegliasco (Marseille, France), E. Van Ganse (Lyon, France)
| |
Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study
Y. Minakata (Wakayama, Japan), T. Motegi (Tokyo, Japan), J. Ueki (Chiba, Japan), Y. Gon (Tokyo, Japan), T. Seki (Tokyo, Japan), T. Anzai (Tokyo, Japan), S. Nakamura (Tokyo, Japan), K. Hirata (Osaka, Japan), M. Ichinose (Sendai, Japan)
| |
Effect of tiotropium/olodaterol combination therapy on long-term heart rate and blood pressure in COPD patients
S. Andreas (Göttingen, Germany), L. Mcgarvey (Belfast, United Kingdom), U. Bothner (Ingelheim am Rhein, Germany), M. Trampisch (Ingelheim am Rhein, Germany), A. De La Hoz (Ingelheim am Rhein, Germany), M. Fležar (Golnik, Slovakia), . Alter (Marburg, Germany), R. Buhl (Mainz, Germany)
| |
Effects of Inhaled Long Acting Muscarinic Antagonist (LAMA) on Lung Functions in Adult Stable Bronchiectasis
M. Tungnantawiwat (Bangkok, Thailand), K. Kitinarong (Bangkok, Thailand)
| |
AMPLIFY: efficacy of aclidinium vs tiotropium in COPD
S. Sethi (Buffalo, United States of America), E. Kerwin (Medford, United States of America), H. Watz (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, United States of America), R. Mroz (Bialystok, Poland), R. Segarra (Barcelona, Spain), E. Molins (Barcelona, Spain), D. Jarreta (Barcelona, Spain), E. Garcia-Gil (Barcelona, Spain)
| |
Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
D. Halpin (Exeter, United Kingdom), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), K. Mezzi (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Gupta (Hyderabad, India), K. Kostikas (Basel, Switzerland), J. Wedzicha (London, United Kingdom)
| |